The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Candidemia is a bloodstream fungal infection caused by Candida species and is most commonly observed in hospitalized patients. Even with proper antifungal drug treatment, mortality rates remain high at 40-50%. Therefore, prophylactic or preemptive antifungal medications are currently recommended in order to prevent infections in high-risk patients. Moreover, the majority of women experience at least one episode of vulvovaginal candidiasis (VVC) throughout their lifetime and many of them suffer from recurrent VVC (RVVC) with frequent relapses for the rest of their lives. While there currently exists no definitive cure, the only available treatment for RVVC is again represented by antifungal drug therapy. However, due to the limited number of existing antifungal drugs, their associated side effects and the increasing occurrence of drug resistance, other approaches are greatly needed. An obvious prevention measure for candidemia or RVVC relapse would be to immunize at-risk patients with a vaccine effective against Candida infections. In spite of the advanced and proven techniques successfully applied to the development of antibacterial or antiviral vaccines, however, no antifungal vaccine is still available on the market. In this review, we first summarize various efforts to date in the development of anti-Candida vaccines, highlighting advantages and disadvantages of each strategy. We next unfold and discuss general hurdles encountered along these efforts, such as the existence of large genomic variation and phenotypic plasticity across Candida strains and species, and the difficulty in mounting protective immune responses in immunocompromised or immunosuppressed patients. Lastly, we review the concept of ‘trained immunity’ and discuss how induction of this rapid and nonspecific immune response may potentially open new and alternative preventive strategies against opportunistic infections by Candida species and potentially other pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidiasis (caused by Candida species) is the most common opportunistic fungal infection and the fourth most common nosocomial bloodstream infection (6, 7).”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“org April 2018 | Volume 9 | Article 897 and use of broad-spectrum antibiotics (4, 5).”
BackgroundTreg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Trained immunity: A program of innate immune memory in health and– disease
Netea, M. G., Joosten, L. A. B., Latz, E., Mills, K. H. G., Natoli, G., Stunnenberg, H. G., O’Neill, L. A. J., & Xavier, R. J. (2016) · Science · doi:10.1126/science.aaf1098 · Cited by 2,768
Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.003 · Cited by 2,614 · cited 2×
“One such mechanism, which likely resulted from the coevolution of bacterial microbiota, commensal fungi and host immune system, relies on the metabolic tryptophan-AhR pathway and 2,3-indoleamine dioxygenase (IDO) (113, 114).”
BackgroundRound, J. L., & Mazmanian, S. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909122107 · Cited by 2,233
Nonfilamentous C. albicans Mutants Are Avirulent
Lo, H.-J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., & Fink, G. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80358-x · Cited by 1,809
Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity
Saeed, S., Quintin, J., Kerstens, H. H. D., Rao, N. A., Aghajanirefah, A., Matarese, F., Cheng, S.-C., Ratter, J., Berentsen, K., van der Ent, M. A., et al. (2014) · Science · doi:10.1126/science.1251086 · Cited by 1,761
Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A. B., Ifrim, D. C., Saeed, S., Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202870109 · Cited by 1,728 · cited 1×
“albicans infection through a T and B lymphocyte-independent mechanism (134).”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Quintin, J., Saeed, S., Martens, J. H. A., Giamarellos-Bourboulis, E. J., Ifrim, D. C., Logie, C., Jacobs, L., Jansen, T., Kullberg, B.-J., Wijmenga, C., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.06.006 · Cited by 1,289
Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis
Naglik, J. R., Challacombe, S. J., & Hube, B. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.3.400-428.2003 · Cited by 1,179 · cited 1×
“albicans, which are required for adhesion, epithelial, and endothelial invasion and fungal cell metabolism (54, 55).”
BackgroundAn integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946 · cited 1×
“In fact, the Candida cell wall represents a hub of pathogen-associated molecular pattern (PAMP)–pathogen recognition receptor (PRR) interactions that dictate downstream immune responses (61).”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 2×
“tropicalis constitutes 20–45% of Candida isolates in the Asia-Pacific region (18) and invasive candidiasis due to this species is commonly associated with patients with neutropenia and malignancy (106).”
BackgroundGlobal trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680
Noble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Saville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 1×
“While direct penetration into the mucosal surfaces by the hyphal form is important for invasion, widespread dissemination through the bloodstream and to the organs is thought to be facilitated by the yeast form (84).”
BackgroundChanging epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524 · cited 1×
“org April 2018 | Volume 9 | Article 897 and use of broad-spectrum antibiotics (4, 5).”
BackgroundA novel glyco-conjugate vaccine against fungal pathogens
Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050749 · Cited by 442
Candida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366 · cited 1×
“Despite the best available standards of care, the incidence of candidemia, a sign of invasive or systemic candidiasis, is on the rise in the US (8) and mortality rates often exceed 50% despite use of antifungal drugs (9).”
BackgroundMucosal damage and neutropenia are required for Candida albicans dissemination
Koh, A. Y., Köhler, J. R., Coggshall, K. T., Van Rooijen, N., & Pier, G. B. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040035 · Cited by 360 · cited 1×
“albicans hyphal formation might be critical for this ability (82).”
BackgroundAn isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1
Selmecki, A., Gerami‐Nejad, M., Paulson, C., Forche, A., & Berman, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06176.x · Cited by 325 · cited 1×
“One of the well-known examples is the identification of an isochromosome composed of two copies of the left arm of chromosome 5, which is associated with azole resistance (17) due to amplification of two resistance genes, ERG11 and TAC1 (96).”
BackgroundGenetic and phenotypic intra-species variation in Candida albicans
Hirakawa, M. P., Martinez, D. A., Sakthikumar, S., Anderson, M. Z., Berlin, A., Gujja, S., Zeng, Q., Zisson, E., Wang, J. M., Greenberg, J. M., et al. (2015) · Genome Research · doi:10.1101/gr.174623.114 · Cited by 320
Pande, K., Chen, C., & Noble, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2710 · Cited by 306 · cited 1×
“albicans in the GI tract of antibiotic-treated mice (94).”
BackgroundOrgan-Specific Innate Immune Responses in a Mouse Model of Invasive Candidiasis
Lionakis, M. S., Lim, J. K., Lee, C.-C. R., & Murphy, P. M. (2011) · Journal of Innate Immunity · doi:10.1159/000321157 · Cited by 302
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294 · cited 1×
“While this figure has remained largely unchanged, the relative ranking between these species has seen significant shifts in different regions over the past decades (100).”
BackgroundVermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 1×
“now being reported all over the world (22, 23).”
BackgroundDaniels, C. C., Rogers, P. D., & Shelton, C. M. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.1.27 · Cited by 273 · cited 1×
“A replacement of the seven-valent pneumococcal conjugate vaccine (PCV7) with PCV13 covering additional six of the most prevalent serotypes that are not included in PCV7 successfully reduced the burden of pneumococcal disease in pediatric populations (127).”
BackgroundCandida colonisation as a source for candidaemia
Miranda, L. N., van der Heijden, I. M., Costa, S. F., Sousa, A. P. I., Sienra, R. A., Gobara, S., Santos, C. R., Lobo, R. D., Pessoa, V. P., & Levin, A. S. (2009) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.02.009 · Cited by 250 · cited 1×
“albicans isolated from the blood of patients with candidiasis often matches those recovered from the GI tract of the same patients (81), suggesting that C.”
BackgroundGenomic Plasticity of the Human Fungal Pathogen Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2010) · Eukaryotic Cell · doi:10.1128/ec.00060-10 · Cited by 247 · cited 1×
“albicans to rapidly adapt to an adverse environment by changing the copy number of specific genes on a given chromosome (95).”
BackgroundVermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
Bassetti, M., Merelli, M., Righi, E., Diaz-Martin, A., Rosello, E. M., Luzzati, R., Parra, A., Trecarichi, E. M., Sanguinetti, M., Posteraro, B., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01998-13 · Cited by 228 · cited 1×
“albicans is still considered the most common species causing candidemia, increasing rates of NAC species in candidemia have been reported worldwide (18, 101, 102).”
BackgroundSpellberg, B. J., Ibrahim, A. S., Avanesian, V., Fu, Y., Myers, C., Phan, Q. T., Filler, S. G., Yeaman, M. R., & Edwards, Jr. (2006) · The Journal of Infectious Diseases · doi:10.1086/504691 · Cited by 180 · cited 1×
“Vaccination with the recombinant N-terminus of Als3 (rAls3p-N) induced a stronger antibody response and survival rate compared with the rAls1p-N vaccine, and was more effective than rAls1p-N in the murine model of oropharyngeal and vaginal candidiasis (37).”
ResultLionakis, M. S., Fischer, B. G., Lim, J. K., Swamydas, M., Wan, W., Richard Lee, C.-C., Cohen, J. I., Scheinberg, P., Gao, J.-L., & Murphy, P. M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002865 · Cited by 118 · cited 1×
“For instance, mice lacking the chemokine receptor Ccr1, which is critical for neutrophil recruitment, display improved renal function during invasive candidiasis (118) and administration of Ccr1 antagonists reduces renal tissue injury and improves survival in mice challenged with systemic candidiasis (119).”
BackgroundExcess Costs of Hospital Care Associated With Neonatal Candidemia
Smith, P. B., Morgan, J., Benjamin, D. K., Fridkin, S. K., Sanza, L. T., Harrison, L. H., Sofair, A. N., Huie-White, S., & Benjamin, D. K. (2007) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000253973.89097.c0 · Cited by 65
Luo, G., Ibrahim, A. S., French, S. W., Edwards, J. E., & Fu, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025909 · Cited by 62 · cited 1×
“tropicalis in both immunocompetent and neutropenic mice (43).”
Background
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Sánchez-Ramón, S., Conejero, L., Netea, M. G., Sancho, D., Palomares, Ó., & Subiza, J. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02936 · Cited by 262
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective
Rosati, D., Bruno, M., Jaeger, M., ten Oever, J., & Netea, M. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020144 · Cited by 206
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
“There are different challenges in this area of research including fungal extensive variation and plasticity, the presence of preestablished immunological tolerance as well as the challenges in advancing protective memory responses in patients strugling with impaired adaptive immunity [141].”
BackgroundVaccines for human fungal diseases: close but still a long way to go
Oliveira, L. V. N., Wang, R., Specht, C. A., & Levitz, S. M. (2021) · npj Vaccines · doi:10.1038/s41541-021-00294-8 · Cited by 135
Metadata
- Authors
- Tso, G. H. W., Reales-Calderon, J. A., & Pavelka, N.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-04-27
- Volume
- 9
- Pages
- 897-897
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2799848852
- Cited by
- 78
- References
- 41
- FWCI
- 5.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.